Document Detail


A controlled trial of GL enzyme in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  3046747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
GL enzyme (hyaglosidase) is a highly purified component enzyme of hyaluronidase. A therapeutic trial was carried out in the treatment of suspected myocardial infarction among 1,488 patients presenting within 6 h of the onset of symptoms. No significant reduction in mortality at 6 months was observed in the GL group (15.7%) compared with the placebo group (16.4%). Mortality at 2 weeks was also unaffected by treatment (GL 10.3%; placebo 10.9%).
Authors:
D G Julian; J M Simpson; P J Cadigan; M C Petri; R J Hall; R H Smith; B L Pentecost
Related Documents :
2688327 - Anaphylactic reaction to streptokinase with first exposure: case report and review of t...
15620927 - Three-day magnesium administration prevents atrial fibrillation after coronary artery b...
6499697 - Magnesium in coronary artery disease.
21429987 - Extensive scar formation and regression during heart regeneration after cryoinjury in z...
20514307 - The significance of repetitive ventricular responses induced by radiofrequency energy a...
24824697 - Age-related features of cytoflavin effectiveness during experimental myocardial ischemia.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiology     Volume:  75     ISSN:  0008-6312     ISO Abbreviation:  Cardiology     Publication Date:  1988  
Date Detail:
Created Date:  1988-10-19     Completed Date:  1988-10-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1266406     Medline TA:  Cardiology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  177-83     Citation Subset:  IM    
Affiliation:
Freeman Hospital, Newcastle-upon-Tyne, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Female
Follow-Up Studies
Humans
Hyaluronoglucosaminidase / therapeutic use*
Male
Middle Aged
Myocardial Infarction / drug therapy*,  mortality
Random Allocation
Time Factors
Chemical
Reg. No./Substance:
EC 3.2.1.35/Hyaluronoglucosaminidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients.
Next Document:  Neuronal systems immunoreactive with antiserum to lamprey gonadotropin-releasing hormone in the brai...